Product Information
CARBIDOPA-LEVODOPA 25-250 TAB is a generic product labeled by ScieGen Pharmaceuticals Inc., priced at $0.1094 per EA under NDC 50228045905. Its NADAC has been published 260 times since Sep 1, 2021.
FDA first approved this application on May 7, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 250 mg/1; mg/1
Manufacturer
ScieGen Pharmaceuticals Inc.NDC
50228045905
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA214092FDA Approved
5/7/2021
TE Code
AB
On Market Since
5/7/2021
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has been published 260 times since Sep 1, 2021, and over the history we have for it it has declined 35.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1094 per EA |
|---|---|
| All-time high | $0.1761 (Oct 13, 2021) |
| All-time low | $0.0731 (Apr 17, 2024) |
| 52-week high | $0.1334 |
| 52-week low | $0.1085 |
| Median price | $0.1381 |
| Average price | $0.1349 |
| Largest weekly change | +71.8% (Jun 19, 2024) |
| Weeks tracked | 260 |
| Tracking since | Sep 1, 2021 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA 25-250 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA 25-250 TAB, manufactured by ScieGen Pharmaceuticals Inc., is $0.1094 per EA (NDC 50228045905), effective Aug 19, 2026.
How has the price of CARBIDOPA-LEVODOPA 25-250 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has declined 35.0%. It has been tracked across 260 weekly CMS publications since Sep 1, 2021.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA 25-250 TAB?
Since Sep 1, 2021, the NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has ranged from a low of $0.0731 (Apr 17, 2024) to a high of $0.1761 (Oct 13, 2021), with a median of $0.1381 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA 25-250 TAB?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CARBIDOPA-LEVODOPA 25-250 TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures CARBIDOPA-LEVODOPA 25-250 TAB?
CARBIDOPA-LEVODOPA 25-250 TAB (NDC 50228045905) is labeled by ScieGen Pharmaceuticals Inc., and CMS classifies it as a generic product.